Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc. has demonstrated considerable growth potential, as evidenced by its average selling price (ASP) rising to $441 per test, reflecting a year-over-year increase of 9.2% alongside a 16% increase in volume for the quarter. The company has posted a year-to-date revenue growth of 19%, fueled by balanced increases in ASP and testing volumes, contributing to a positive trend in operational performance. Additionally, Exagen's cash position improved to $35.7 million, supporting its ongoing efforts to enhance its commercial strategies and expand its market presence to 45 territories by the end of 2025.

Bears say

Exagen Inc's financial performance has exhibited concerning trends, particularly in its second and third quarter results, despite an initial revenue beat of $17.2 million. The company experienced a significant reduction in workforce, with a 42 full-time equivalent (FTE) headcount decrease, impacting its sales, research and development, and other functions, which raises concerns about its operational efficiency and strategic focus. Furthermore, the persistent GAAP EPS loss of -$0.21, coupled with an EBITDA loss of $1.9 million and inconsistent revenue recognition, contributes to a negative outlook for the company's financial stability and growth potential.

Exagen Inc (XGN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.